1488-02-4 Usage
General Description
3-Phenyl-3-pyrrolidinol HCl, also known as Guaifenesin, is a medication used to treat coughs and congestion associated with colds, bronchitis, and other respiratory illnesses. It works by thinning and loosening mucus in the airways, making it easier to cough up. The HCl in its name refers to the hydrochloride salt form of the compound, which is commonly used in pharmaceuticals to improve stability and solubility. Guaifenesin is considered safe and effective for relieving chest congestion and coughing, and is available in various forms including tablets, syrups, and lozenges. It is important to follow dosing instructions and consult a healthcare professional before using this medication, especially for individuals with certain medical conditions or taking other medications.
Check Digit Verification of cas no
The CAS Registry Mumber 1488-02-4 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 1,4,8 and 8 respectively; the second part has 2 digits, 0 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1488-02:
(6*1)+(5*4)+(4*8)+(3*8)+(2*0)+(1*2)=84
84 % 10 = 4
So 1488-02-4 is a valid CAS Registry Number.
InChI:InChI=1/C10H13NO.ClH/c12-10(6-7-11-8-10)9-4-2-1-3-5-9;/h1-5,11-12H,6-8H2;1H
1488-02-4Relevant articles and documents
DOPAMINE D2 RECEPTOR LIGANDS
-
Page/Page column 222, (2016/07/05)
The present invention relates to novel dopamine D2 receptor ligands. The invention further relates to functionally-biased dopamine D2 receptor ligands and the use of these compounds for treating or preventing central nervous system and systemic disorders associated with dysregulation of dopaminergic activity. The present invention relates to novel compounds that modulate dopamine D2 receptors. In particular, compounds of the present invention show functional selectivity at the dopamine D2 receptors and exhibit selectivity downstream of the D2 receptors, on the 0- arrestin pathway and/or on the cAMP pathway.
